Incannex Healthcare Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
64.3%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$2.48next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q1 FY2027 Quarterly Report (Form 10-Q) Filing | 14 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly74.5MTarget: Sufficient to fund operations and capital expenditures for at least 12 months
Net Loss (Nine Months Ended March 31, 2026) Quarterly16.8MTarget: Minimize cash burn while advancing clinical trials
Shares Repurchased under Share Repurchase Program Quarterly2.1MTarget: Up to $20 million total authorization
Watch Items
- DReAMzz Phase 2 Crossover Dose-Optimization Study for IHL-42XTrigger: Completion of patient dosing and release of topline dataAction: Evaluate efficacy and safety profile to optimize active pharmaceutical ingredient ratios before initiating Phase 3
- PSX-001 Phase 2b Clinical Trial for Generalized Anxiety DisorderTrigger: Initiation of multi-jurisdiction Phase 2b trial in the US and UKAction: Monitor patient enrollment rates and initial safety/efficacy readouts
- Remediation of Material Weakness in Internal ControlsTrigger: Implementation of enhanced control procedures and auditor validationAction: Ensure timely and accurate financial reporting to prevent administrative errors
Research as of 19 Jun 2026